Background: Cardiovascular (CV) mortality is higher in patients with rheumatoid arthritis (RA), in particular when anti-citrullinated protein antibodies (ACPA) are present. Recently, ACPA have also been described in a cohort of patients without RA, but with coronary artery disease (CAD). It is however unknown if ACPA can consistently be found in patients with CAD, and if ACPA are associated with mortality in these patients. The purpose of this study was to assess the relationship between ACPA and long-term outcomes including mortality in patients with ST-elevation myocardial infarction (STEMI) without RA.
Introduction
Inflammatory processes are known to play a key role in the development of coronary artery disease (CAD). Coronary atherosclerotic lesions are characterized by macrophage activation, fibrosis, production of matrix metalloproteinases (MMPs) and lipid deposition, factors which are associated with chronic low-grade inflammation. This might be the reason that CAD and vulnerable plaques are more prevalent in patients with chronic inflammatory diseases like rheumatoid arthritis (RA) (1) .
In RA approximately 60% of patients harbor antibodies directed against citrullinated proteins: socalled anti-citrullinated protein antibodies (ACPA) (2) . Citrulline is a post-translational modification of the amino acid arginine by the enzyme peptidylarginine deiminase (PAD), a process that frequently occurs in the context of inflammation (3) . Interestingly, it has been shown that the cardiovascular risk is significantly higher in ACPA-positive versus ACPA-negative RA patients (4) . Furthermore, it has been reported that citrullination of proteins also occurs in myocardium and atherosclerotic lesions (5, 6) . Although ACPA is thought to be very specific for RA (98%) (7) , a recent study surprisingly found that 10% of the CAD patients without RA were ACPA-positive (8) . Likewise, rheumatoid factor (RFhas also been reported to be associated with a high cardiovascular risk in patients without RA (ref This raises the question whether 1) ACPA can consistently be found in non-RA patients with CAD and 2) whether ACPA are associated with mortality in these patients. Therefore, we investigated if ACPA are associated with long-term mortality and re-infarction in patients without RA with established CAD.
Methods

Patients and outcomes
The present study used data from patients with ST-segment elevation myocardial infarction (STEMI), who were included in the MISSION! Intervention Trial. The MISSION! Intervention Trial was conducted from February 2004 to October 2006 and investigated the use of either Bare Metal Stents (BMS) or Sirolimus Eluting Stents (SES) during primary percutaneous coronary intervention (PCI). (9) All patients were treated according to the institutional STEMI protocol, based on guidelines of the European Society of Cardiology, American College of Cardiology and the American Heart Association. (10, 11) At inclusion, data were collected regarding patient demographics, risk factors and clinical characteristics. SYNTAX score was used to assess CAD complexity by using baseline angiographic images obtained during the index procedure after reperfusion of the culprit segment (12) . Calculations were performed by an experienced interventional cardiologist. Patients with prior myocardial infarction (n=11) or prior revascularization (n=7) were excluded. In addition, chart review was performed for all ACPA-positive patients to determine whether they had a previous rheumatic disease, or developed a rheumatic disorder during the long-term follow-up period . These patients (n=8) were also excluded for analysis. To investigate long-term outcome, 10 year all-cause mortality and the combined endpoint of 10 year all-cause mortality and re-infarction (with and without STsegment elevation) was assessed. Information on all-cause mortality was obtained from the Dutch Municipality Records registry. Cause of death was retrieved from general practitioners. Follow-up data on serious adverse events including myocardial infarction, new revascularisation and stroke was obtained by telephone interviews at 2, 5 and 10 years after admission. The study was approved by the institutional ethical committee. Written informed consent was obtained from all patients before enrolment in the study.
Autoantibody testing
Baseline serum samples drawn before primary PCI were used ACPA analysis. ACPA positivity was determined using a commercially available ELISA system for anti-CCP3 testing (Quanta Lite™ CCP3.1 IgG/IgA Cat# 704550, INOVA Diagnostics Inc., US). According to supplier's manual, values above 20 aU/mL were considered positive. ACPA-levels in patients from the MISSION Intervention trial were compared with ACPA-levels derived from sera of 160 healthy controls aged between 20 and 70 years from the Leiden area (13) .
Statistical analysis
Normally distributed continuous variables were reported as mean and standard deviation, and compared with Student's t-test. Skewed distributed continuous variables were reported as median and interquartile range, and compared with Mann-Whitney U test. Categorical variables were reported as number and percentage, and compared with Pearson's chi-square test. Event-free survival was analyzed with Kaplan-Meier estimates and compared between groups with the log-rank test. Cox regression was performed to assess the association between the ACPA-positivity and primary and secondary outcome measures. Other variables used for the analysis included: sex, BMI, previous hypertension and/or smoking, out of hospital cardiac arrest, anterior infarction, infarct size, number of vessels diseased (>50%), complete revascularization, culprit vessel, proximal lesion, TIMI flow before intervention and drug-eluting stent during primary PCI. Variables were used in multivariable models in case the univariable p-value was <0.10. All statistical tests were performed with SPSS software (Version 22.0, SPSS IBM Corp., Armonk, New York). P-Values <0.05 assessed by two-sided tests were considered to be statistically significant.
Results
A total of 275 STEMI patients from the MISSION! Intervention study had no history of RA or RA during the follow-up period and were included in the analysis. A positive ACPA test was found in 11% (29/275) of the included patients, which is significantly more than the 2% (3/160) of ACPA positive tests in a healthy control population (p-Value < 0.01) ( Figure 1 ). ACPA-positive and ACPA-negative patients did not differ significantly with regard to demographics, risk factors, clinical and angiographic characteristics. However, there were some differences between ACPA-positive and ACPA-negative patients that reached no statistical significance: age, female sex, infarct size, multi-vessel CAD and Creactive protein (CRP) levels (Table 1) Table 2 ). No significant correlation was found between ACPA levels and continuous SYNTAX scores (p= 0.392).
Discussion
Key findings of this study are: 1) approximately 11% of non-RA patients with established CAD are ACPA-positive, corroborating previous results, and 2) ACPA-positivity is independently associated with long-term mortality and/or re-infarction in these patients.
ACPA are widely recognized as the most disease-specific marker for RA. Moreover, ACPA are associated with a more severe disease course in RA with e.g. more joint destruction. The most potent risk factors for RA have been shown to be specifically associated with ACPA-positive disease: genetic features (HLA, the majority of predisposing SNPs) and smoking (14) . This raises the question whether these factors are also associated with the presence of ACPA in RA-negative patients. In this study, current smoking status was not significantly different between ACPA-positive and -negative CAD patients. Further studies are therefore required to elucidate whether genetic predisposition is also associated with ACPA development in CAD patients without RA.
Interestingly, we also found an association between ACPA levels and long-term clinical outcomes in patients with ACPA levels below the cutoff of 20 aU/mL (data not shown). This cut-off yields optimal sensitivity and specificity for diagnosing RA, but lower levels might well be meaningful in other settings. Our findings indicate that even low ACPA levels might play a role in the progression of CAD.
The association between ACPA and with long-term outcome in patients with CAD without RA in our study, is in line with the current evidence of the prognostic role of ACPA in patients with RA for development of either cardiovascular (CV) disease and death (Hansson et al., 2011, 14, 15) . The fact that we now find an association between ACPA and CAD in the absence of RA, raises interest in the role of these autoantibodies and anti-citrulline autoimmunity in the atherosclerotic disease process.
One could envisage a contribution of these autoantibodies to atherosclerosis in the following manner: citrullinated proteins have been demonstrated in both atherosclerotic plaques and perivascular interstitium (5, 6) . If ACPA bind to these proteins, it appears likely that they would be able to exert their known effects of complement activation and the engagement of Fc-receptors on macrophages, leading to the production of inflammatory cytokines (7, 14) . This could augment the inflammatory processes already taking place in the vessel walls in the context of atherosclerosis. Therefore the presence of ACPA, both in patients with and without RA, could accelerate plaque formation and rupture, and thereby lead to increased mortality (3).
The exact citrullinated antigens in the vasculature remain to be identified. In clinical studies including patients with RA, high levels of ACPA targeting specifically citrullinated histone 2B were associated with subclinical atherosclerosis, whereas the association between ACPA targeting citrullinated fibrinogen and subclinical atherosclerosis could not be demonstrated (16, 17) .
Enhancement of the inflammatory process of atherosclerosis by ACPA would explain why the rate of ACPA-positivity is significantly higher in patients with STEMI compared to healthy controls, and why these patients have a higher risk of re-infarction and/or death. We determined if advanced coronary atherosclerosis (as measured by the SYNTAX score after reperfusion) was in the causal pathway of ACPA-positivity and re-infarction and/or death by adjusting the multivariable analyses for SYNTAXscore. However, ACPA-positivity remained significantly associated with the clinical outcomes. There are several possible explanations for this finding; either SYNTAX-score may in this case not completely capture or reflect coronary atherosclerosis, or ACPA might exert their effect via a different pathway.
The association between ACPA-positivity and progressive CAD warrants further study. If ACPA are indeed found to be pro-atherogenic, this may alter the common concept of the pathophysiology of CVD. As a consequence, immunosuppression could become a novel treatment option, as is already being investigated. (18) Additionally, if future research confirms our findings, ACPA could be a new biomarker for CVD and predict a worse long-term outcome.
Limitations
This study is the first to describe the association of long-term mortality and/or re-infarction and ACPA in patients without RA. Limitations of the current study are the observational study design, precluding conclusions about causality, and the use of 1 cohort with a limited sample size. Therefore, we were unable to test associations in subgroups, restricting the applicability of the findings to other patient groups. However, the results of our study confirm previous findings, indicating reproducibility.
Strengths are the long duration of follow-up and stringent control for and exclusion of patients who developed RA. The treatment according to a strict protocol both in-hospital and during outpatient clinical follow-up excludes the possibility that differences in treatment account for the observed results.
Conclusion
In conclusion, we found that the presence of ACPA was independently associated with long-term mortality and/or re-infarction in patients with myocardial infarction without RA. ACPA might therefore act as an independent pro-atherogenic factor in patients both with and without RA. Future research is required to provide more insight into the development of anti-citrulline autoimmunity in patients with CAD without RA, and into the underlying mechanism causing more progressive CAD in these patients. Abbreviations: ACPA, anti-citrullinated protein antibodies; BMI, body mass index; CABG, coronary artery bypass graft surgery; CVD, cardiovascular disease; PCI, percutaneous coronary intervention *Causes of death were:
Figure legends
in ACPA-negative patients: COPD (2), CVA (1), heart failure (3), infection (2), malignancy (10), myocardial infarction (4), sudden cardiac death (2), unknown (3);
in ACPA-positive patients: Heart failure (1), liver failure (1), malignancy (2), myocardial infarction (2), sudden cardiac death (1), unknown (1) . † Defined as systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg and/or the use of antihypertensive medication. ‡ Serum total cholesterol ≥6.0 mmol/L and/or serum TG ≥2.2 mmol/L or treatment with lipid lowering drugs.
